Elafibranor 120 mg ( DrugBank: Elafibranor )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
93	原発性胆汁性胆管炎	1
94	原発性硬化性胆管炎	1

93. 原発性胆汁性胆管炎

臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03124108 (ClinicalTrials.gov)	April 5, 2017	28/3/2017	Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangiti ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy ...	Primary Biliary Cholangitis (PBC)	Drug: Elafibranor 80 mg;Drug: Elafibranor 120 mg;Drug: Placebo	Genfit	NULL	Completed	18 Years	75 Years	All	45	Phase 2	United States;France;Germany;Spain;United Kingdom

臨床試験数 : 148 / 薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05627362 (ClinicalTrials.gov)	January 27, 2023	22/11/2022	A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Scleros ...	A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term ...	Primary Sclerosing Cholangitis	Drug: Elafibranor 80 mg;Drug: Elafibranor 120 mg;Drug: Placebo Matched to Elafibranor 80 mg;Drug: Pl ...	Ipsen	NULL	Recruiting	18 Years	75 Years	All	60	Phase 2	United States